AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9402071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside (zidovudine 600 mg/day and zalcitabine 2.25 mg/day)
Number of subjects: 63
Study 9402071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mIU interferon-alpha2a
Number of subjects: 63
Study 9402071 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mIU interferon-alpha2a
Number of subjects: 63
Study 9402071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside + 1-mIU interferon
Number of subjects: 63
Study 9402071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside + 6-mIU interferon
Number of subjects: 63
Study 9402071 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 63
Study 8214960 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric decompression maintained postoperatively until resumption of bowel function (Group 1)
Number of subjects: 77
Study 8214960 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube removed in the recovery room (Group 2)
Number of subjects: 77
Study 8214960 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 77
Study 8214960 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 77
Study 3659583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (30 mg)
Number of subjects: 19
Study 3659583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan + Salbutamol (30 mg + 2 mg)
Number of subjects: 19
Study 3659583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29677619 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood adversities
Number of subjects: 221
Study 29677619 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental problems
Number of subjects: 221
Study 29677619 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollected family unhappiness
Number of subjects: 221
Study 27207493 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cold gel pack
Number of subjects: 180
Study 27207493 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cold-hot gel pack
Number of subjects: 180
Study 27207493 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 25049242 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-PQ with 8.5 g fat (group B)
Number of subjects: 30
Study 25049242 — intervention group
Group type: COMPARATOR
Intervention: DHA-PQ without fat (group A)
Number of subjects: 30
Study 22946930 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ibandronate 3 mg every 3 months for 12 months
Number of subjects: 129
Study 22946930 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo every 3 months for 12 months
Number of subjects: 129
Study 20012857 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 218
Study 20012857 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 218
Study 20012857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise
Number of subjects: 218
Study 20012857 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 218
Study 20012857 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 218
Study 18940086 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a radio transmission (oral medium)
Number of subjects: 0
Study 18940086 — intervention group
Group type: COMPARATOR
Intervention: Reading a transcription of a radio transmission (written medium)
Number of subjects: 0
Study 17217107 — intervention group
Group type: EXPERIMENTAL
Intervention: Open hemorrhoidectomy for stage II hemorrhoidal disease
Number of subjects: 97
Study 17217107 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed hemorrhoidectomy for stage III hemorrhoidal disease
Number of subjects: 97
Study 17217107 — intervention group
Group type: EXPERIMENTAL
Intervention: Long's method (stapling device) for stage III hemorrhoidal disease
Number of subjects: 97
Study 12888874 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (subcutaneous, twice daily)
Number of subjects: 68
Study 12888874 — intervention group
Group type: COMPARATOR
Intervention: UFH (intravenous)
Number of subjects: 68
Study 10981841 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of majority position (majority-to-minority change)
Number of subjects: 2
Study 10981841 — intervention group
Group type: COMPARATOR
Intervention: Gain of majority position (minority-to-majority change)
Number of subjects: 2
Study 9368703 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acarbose
Number of subjects: 24
Study 9368703 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acarbose plus 10 ml antacid suspension
Number of subjects: 24
Study 9368703 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml antacid suspension
Number of subjects: 24
Study 9368703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1334819 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of eligible patients cared for by medical staff other than private attending physicians
Number of subjects: 112
Study 1334819 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a nurse coordinator at the site
Number of subjects: 112
Study 1334819 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of nurse coordinator full-time equivalents at the site
Number of subjects: 112
Study 1334819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer other clinical trials for which the nurse coordinator was responsible
Number of subjects: 112
Study 1334819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer perceived obstacles to enrollment
Number of subjects: 112
Study 3887887 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g naturally labeled 13C carbohydrate after high fat antecedent diet
Number of subjects: 14
Study 3887887 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g naturally labeled 13C carbohydrate after mixed antecedent diet
Number of subjects: 14
Study 3887887 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g naturally labeled 13C carbohydrate after high carbohydrate antecedent diet
Number of subjects: 14
Study 28738709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline solution (HSS) twice daily
Number of subjects: 100
Study 28738709 — intervention group
Group type: COMPARATOR
Intervention: Control group with VAP prevention protocol
Number of subjects: 100
Study 27167367 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (axillary ultrasound, laser, and postisometric facilitation technique)
Number of subjects: 45
Study 27167367 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (axillary ultrasound and laser applied to the axillary region)
Number of subjects: 45
Study 27167367 — intervention group
Group type: COMPARATOR
Intervention: Group A (standard care with traditional physical therapy)
Number of subjects: 45
Study 25050903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of ultrasound-guided laser ablation therapy (LAT) using a 1064nm Nd-YAG laser source at 3 W output power.
Number of subjects: 200
Study 25050903 — intervention group
Group type: COMPARATOR
Intervention: Follow-up with no treatment (Control group).
Number of subjects: 200
Study 22228439 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal implants
Number of subjects: 22
Study 22228439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20116959 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving Beliefs Questionnaire (CBQ)
Number of subjects: 214
Study 18705707 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-median fluid intake (24 ml/kg/day)
Number of subjects: 63
Study 18705707 — intervention group
Group type: COMPARATOR
Intervention: Below-median fluid intake (16 ml/kg/day)
Number of subjects: 63
Study 16051399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730, 1x10(8) cfu/tablet twice a day for 6 months
Number of subjects: 54
Study 16051399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11824856 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 100 mg/kg
Number of subjects: 29
Study 11824856 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 250 mg/kg
Number of subjects: 29
Study 11824856 — intervention group
Group type: COMPARATOR
Intervention: L-arginine 250 mg/kg with L-NMMA
Number of subjects: 29
Study 11824856 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA before L-arginine infusion
Number of subjects: 29
Study 11824856 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent infusion of L-arginine after L-NMMA
Number of subjects: 29
Study 10073501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan loading test with intravenous injection of 7.5 mg HYA
Number of subjects: 21
Study 10073501 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=15)
Number of subjects: 21
Study 7722709 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein-energy supplement (Atole)
Number of subjects: 0
Study 7722709 — intervention group
Group type: COMPARATOR
Intervention: Low-energy, no-protein supplement (Fresco)
Number of subjects: 0
Study 2183665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 800 mg three times daily
Number of subjects: 12
Study 2183665 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam, 20 mg daily
Number of subjects: 12
Study 2183665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac, 200 mg twice daily
Number of subjects: 12
Study 2183665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, piroxicam, and sulindac (combined)
Number of subjects: 12
Study 6276883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D analogues (1 alpha hydroxyvitamin D3 or dihydrotachysterol, n = 12)
Number of subjects: 21
Study 6276883 — intervention group
Group type: COMPARATOR
Intervention: Calcium therapy (Control group, n = 9)
Number of subjects: 21
Study 31923471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI) 40 IU daily for 24 weeks
Number of subjects: 210
Study 31923471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 210
Study 31923471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI)
Number of subjects: 210
Study 30799103 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day milk feeding with live yeast culture and mannan-rich fraction
Number of subjects: 48
Study 30799103 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day milk feeding with live yeast culture and mannan-rich fraction
Number of subjects: 48
Study 30799103 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day milk feeding without yeast
Number of subjects: 48
Study 30799103 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day milk feeding without yeast
Number of subjects: 48
Study 30799103 — intervention group
Group type: EXPERIMENTAL
Intervention: Calves fed yeast
Number of subjects: 48
Study 30799103 — intervention group
Group type: EXPERIMENTAL
Intervention: Calves fed milk once a day
Number of subjects: 48
Study 30799103 — intervention group
Group type: EXPERIMENTAL
Intervention: Calves fed milk twice a day
Number of subjects: 48
Study 30799103 — intervention group
Group type: COMPARATOR
Intervention: Calves fed milk once or twice a day
Number of subjects: 48
Study 28497755 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 45
Study 28497755 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 45
Study 26735507 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training (RT)
Number of subjects: 138
Study 25173538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified cardiovascular risk multi‐intervention (n = 50)
Number of subjects: 100
Study 25173538 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 50)
Number of subjects: 100
Study 22893628 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks
Number of subjects: 2046
Study 22893628 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks
Number of subjects: 2046
Study 22893628 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 2046
Study 22893628 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 2046
Study 19458560 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose transdermal E2 (0.014 mg/d)
Number of subjects: 121
Study 19458560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transdermal E2 plus levonorgestrel (0.023 mg/d E2/0.0075 mg/d levonorgestrel)
Number of subjects: 121
Study 19458560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 17766600 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter with extraamniotic saline infusion
Number of subjects: 188
Study 17766600 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter alone
Number of subjects: 188
Study 15099990 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) (25 mg sulfadoxine and 1.25 mg pyrimethamine/kg)
Number of subjects: 117
Study 15099990 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) (25 mg/kg)
Number of subjects: 117
Study 15099990 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 117
Study 15099990 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 117
Study 15099990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 117
Study 11207019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient education (80 patients)
Number of subjects: 162
Study 11207019 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient education (70 patients)
Number of subjects: 162
Study 11207019 — intervention group
Group type: COMPARATOR
Intervention: Peak expiratory flow (PEF)-based self-management
Number of subjects: 162
Study 9784662 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestorage-filtered apheresis platelets
Number of subjects: 0
Study 9784662 — intervention group
Group type: COMPARATOR
Intervention: Bedside-filtered platelets
Number of subjects: 0
Study 9784662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (prestorage-filtered and bedside-filtered)
Number of subjects: 0
Study 8018453 — intervention group
Group type: EXPERIMENTAL
Intervention: Anpirtoline (60 mg orally)
Number of subjects: 16
Study 8018453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (150 mg orally)
Number of subjects: 16
Study 8018453 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg orally)
Number of subjects: 16
Study 8018453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2658483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking intervention and extensive contact with study personnel
Number of subjects: 700
Study 2658483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 700
Study 2658483 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 700
Study 1103074 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyphylline 15 mg/kg
Number of subjects: 7
Study 1103074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31602966 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg extended-release oral trospium 1 h before induction of anesthesia
Number of subjects: 64
Study 31602966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31200321 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg every 3 weeks for a total of 18 doses (∼1 year)
Number of subjects: 1019
Study 31200321 — intervention group
Group type: COMPARATOR
Intervention: placebo every 3 weeks for a total of 18 doses (∼1 year)
Number of subjects: 1019
Study 31200321 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 1019
Study 27892704 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week aerobic exercise programme, 3 times per week (2 supervised sessions and 1 unsupervised session)
Number of subjects: 11
Study 27892704 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group), n=6
Number of subjects: 11
Study 25858012 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the education programme
Number of subjects: 23
Study 25858012 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 23
Study 22840286 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (4 weeks treatment)
Number of subjects: 22
Study 22840286 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment (no medication)
Number of subjects: 22
Study 21294631 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm immersion (FI)
Number of subjects: 25
Study 21294631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice water perfused cooling vest (CV)
Number of subjects: 25
Study 21294631 — intervention group
Group type: COMPARATOR
Intervention: Passive cooling (P)
Number of subjects: 25
Study 19321562 — intervention group
Group type: EXPERIMENTAL
Intervention: HF diet with saturated fat (SE)
Number of subjects: 8
Study 19321562 — intervention group
Group type: EXPERIMENTAL
Intervention: HF diet with monounsaturated fat (UE)
Number of subjects: 8
Study 19321562 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition with saturated fat (SS)
Number of subjects: 8
Study 19321562 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition with monounsaturated fat (US)
Number of subjects: 8
Study 19321562 — intervention group
Group type: EXPERIMENTAL
Intervention: SE and SS treatments
Number of subjects: 8
Study 17083288 — intervention group
Group type: EXPERIMENTAL
Intervention: External reinforcement during motion direction discrimination task
Number of subjects: 2
Study 17083288 — intervention group
Group type: COMPARATOR
Intervention: No external reinforcement during motion direction discrimination task
Number of subjects: 2
Study 17083288 — intervention group
Group type: EXPERIMENTAL
Intervention: External reinforcement during orientation-discrimination sessions
Number of subjects: 2
Study 17083288 — intervention group
Group type: COMPARATOR
Intervention: No external reinforcement during orientation-discrimination sessions
Number of subjects: 2
Study 15103466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileostomy
Number of subjects: 214
Study 15103466 — intervention group
Group type: COMPARATOR
Intervention: No ileostomy
Number of subjects: 214
Study 15103466 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall small bowel obstruction
Number of subjects: 214
Study 15103466 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant obstruction
Number of subjects: 214
Study 15103466 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstruction within 6 weeks of surgery
Number of subjects: 214
Study 11592726 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA supplementation (3.9 g/d for 64 d)
Number of subjects: 6
Study 9638695 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma added to grafts
Number of subjects: 0
Study 9638695 — intervention group
Group type: COMPARATOR
Intervention: No platelet-rich plasma added to grafts
Number of subjects: 0
Study 7988302 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment given by community health centers
Number of subjects: 78
Study 7988302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified dietary and exercise education given by a university outpatient clinic
Number of subjects: 78
Study 3056131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 20
Study 3056131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29855271 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nutritional supplement (140 kcal/serving, 7.9 g protein, multivitamin/minerals, with or without probiotics)
Number of subjects: 208
Study 29855271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplemented groups (with or without probiotics)
Number of subjects: 208
Study 29855271 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 208
Study 27765800 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 μg/d for 12 weeks)
Number of subjects: 324
Study 27765800 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 324
Study 27765800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Number of subjects: 324
Study 26479484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubo aus dem All! - Vorschulalter (intervention group)
Number of subjects: 221
Study 26479484 — intervention group
Group type: COMPARATOR
Intervention: Conventional kindergarten activities (control group)
Number of subjects: 221
Study 24148829 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing calculated 10-year cardiovascular risk (Framingham risk score)
Number of subjects: 0
Study 24148829 — intervention group
Group type: COMPARATOR
Intervention: Control group (received clinical vignettes with all information on risk factors)
Number of subjects: 0
Study 21499703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 461
Study 21499703 — intervention group
Group type: COMPARATOR
Intervention: Gefarnate 50 mg twice daily
Number of subjects: 461
Study 18327581 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 227
Study 18327581 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only (Control)
Number of subjects: 227
Study 18327581 — intervention group
Group type: EXPERIMENTAL
Intervention: Local recurrences
Number of subjects: 227
Study 18327581 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant recurrence
Number of subjects: 227
Study 12747343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine
Number of subjects: 105
Study 12747343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 105
Study 12747343 — intervention group
Group type: COMPARATOR
Intervention: 0.10% ropivacaine
Number of subjects: 105
Study 10584983 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH)
Number of subjects: 15
Study 10584983 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline hormonal profile)
Number of subjects: 15